{"id":"bendamustine-velcade-and-dexamethasone","safety":{"commonSideEffects":[{"rate":"50-60%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL487253","moleculeType":"Small molecule","molecularWeight":"358.27"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bendamustine works by inducing DNA damage and apoptosis in cancer cells, Velcade blocks the proteasome and inhibits protein degradation, Dexamethasone has anti-inflammatory and immunosuppressive effects.","oneSentence":"Bendamustine is a nitrogen mustard alkylating agent that cross-links DNA, Velcade is a proteasome inhibitor that blocks the 26S proteasome, Dexamethasone is a corticosteroid that inhibits phospholipase A2.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:56.540Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT02224729","phase":"PHASE2","title":"Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2014-08-25","conditions":"Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":24},{"nctId":"NCT02424851","phase":"PHASE2","title":"Optimising Renal Outcome in Myeloma Renal Failure","status":"COMPLETED","sponsor":"Oxford University Hospitals NHS Trust","startDate":"2014-11","conditions":"Multiple Myeloma, Chronic Kidney Disease","enrollment":31},{"nctId":"NCT01045681","phase":"PHASE2","title":"Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Intergroupe Francophone du Myelome","startDate":"2010-03-03","conditions":"Multiple Myeloma","enrollment":75},{"nctId":"NCT01484626","phase":"PHASE1, PHASE2","title":"Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma","status":"TERMINATED","sponsor":"Loyola University","startDate":"2011-05-05","conditions":"Multiple Myeloma","enrollment":3},{"nctId":"NCT01526694","phase":"PHASE2","title":"Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM","status":"COMPLETED","sponsor":"Azienda Ospedaliera di Bolzano","startDate":"2012-07","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT01056276","phase":"PHASE2","title":"Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":59},{"nctId":"NCT00740415","phase":"PHASE2","title":"Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2007-06","conditions":"Lymphoma","enrollment":39},{"nctId":"NCT01457144","phase":"PHASE2","title":"Study of Mantle Cell Lymphoma Treatment by RiBVD","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2011-10","conditions":"Mantle Cell Lymphoma","enrollment":76},{"nctId":"NCT01168804","phase":"PHASE2","title":"Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Austrian Forum Against Cancer","startDate":"2010-06","conditions":"Multiple Myeloma","enrollment":79}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Robimustin : Bendamustine","Velcade : Bortezomib","Dexamethasone"],"phase":"phase_2","status":"active","brandName":"Bendamustine, Velcade and Dexamethasone","genericName":"Bendamustine, Velcade and Dexamethasone","companyName":"Intergroupe Francophone du Myelome","companyId":"intergroupe-francophone-du-myelome","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bendamustine is a nitrogen mustard alkylating agent that cross-links DNA, Velcade is a proteasome inhibitor that blocks the 26S proteasome, Dexamethasone is a corticosteroid that inhibits phospholipase A2. Used for Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}